RE:RE:NEWS!I feel the same way about this deal as I felt after the Purefarma acquisition.
Does everyone not get what a game changer this is???
Imagine for a second that every physician in Canada (and in select other countries around the world) will use this genetic diagnostic toolset to tailor a custom cannabis care plan for patients afflicted with pain, anxiety, sleep issues, metabolic problems, addiction, memory impairment, depression or psychosis. Then, pair that care plan with custom formulations developed jointly by Heritage and Endocanna Health and you have a high margin revenue generating machine for years to come. Add that to the world-class extraction capabilities Heritage acquired in the Purefarma deal and you have a medical/extraction behemoth in the making.
Forget about the 3.4 million square foot Leamington greenhouse. Growing mass quantities of dried flower as a profitable business opportunity has already come and gone. Heritage would be much better served to do deals with large LPs who have already made those significant capital investments and who now have a glut of dried flower on their hands. Why build it when you can procure it inexpensively.
Clint, Debra, Graeme, Chris, Don and team know exactly what they are doing. I only hope that investors will one day figure it out and bring the share price up to where it should be.
Patience (and patients) will win out in the long run. GLTA!
Long
AccountabilityM wrote: I’m rather indifferent to this announcement. I’d rather see more greenhouse space (recall the 3.4 million sq ft tomato farm first right of refusal) or an investment in additional oil processing goods.
Customizing oil strains takes away from mass producing bulk goods and scaleability. Now, if this identifies an oil strain that appeals to the masses, that’s one thing, but, if it becomes a cash-sucking science project with unprotected IP, that’s another.
Given Clint’s background, there is more to the “big-picture” why-did-he-do/this than he let’s on.
Cash wise (assuming a 25% foreign exchange), CANN spent $2.5 MM and potentially dilutes our share holding by 2.5 MM shares (again assuming 25% forex and $0.50/share on the closing data). Glad it wasn’t all shares.
Best of luck to all.